Heidi West discusses how academia, government and the pharmaceutical industry can work together to potentially repurpose drugs for the treatment of COVID-19.
List view / Grid view
Filter the results
Lilly, Merck and Pfizer have announced how they will enable their employees to volunteer in programmes to combat COVID-19 while on base pay.
Boehringer Ingelheim and Eli Lilly have received a complete response letter from the US FDA for their sNDA of empagliflozin 2.5mg, an insulin adjunct.
Priority review has been given to the NDA for selpercatinib to treat advanced RET fusion-positive non-small cell lung cancer, RET-mutant medullary thyroid cancer and RET fusion-positive thyroid cancer.
According to Eli Lilly, the company will acquire Dermira in an all-cash transaction for $1.1 billion, at a rate of $18.75 per share.
The first Pharmaceutical Invention Index, which looks at the breadth and depth of novel agents currently being developed within the most innovative pharma pipelines, has been released.
This In-Depth Focus highlights why bio-fluorescent particle detection is an effective method for enumerating present microbes and discusses ICH Q10 knowledge management; presenting five tips for improving your company’s knowledge management.
A new biosimilar drug to treat osteoporosis is now available across Europe after the patent for its reference product expired.
The US District Court has ruled in favour of Eli Lilly in the Alimta patent lawsuit against Dr. Reddy's Laboratories and Hospira, Inc.
A federal judge in the US has said that the Trump administration cannot require pharmaceutical companies to include drug prices in advertisements as it is beyond their authority.
The FDA has given its approval to a new injection for cluster headaches which reduce frequency of attacks.
Eli Lilly presents new data for their mirikizimab treatment for Crohn’s disease.